JAK1 and myeloid neoplasm: Notably, the JAK1/2 inhibitor ruxolitinib has shown efficacy in patients with CSF3R T618I‐positive CNL and anecdotal benefit in other CSF3R‐mutated myeloid neoplasms [24].